Patent intelligence · US
US 10619157
Cancer treatment
Cancer treatment
Patent details — US 10619157
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 14, 2020
- Expiration
- Apr 9, 2040
- Applicant
- Ionis Pharmaceuticals, Inc.
- Claims
- 32
- CPC classes
- A61K, A61K31/7115, A61K31/712, A61K31/7125
Quick answer
US 10619157 (Cancer treatment) is held by Ionis Pharmaceuticals, Inc.. Status: granted. Granted Apr 14, 2020. Expires Apr 9, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Ionis Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 32
- CPC classes
- A61K, A61K31/7115, A61K31/712, A61K31/7125, A61P, A61P35/00
More from Ionis Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12409188
Modulators of HSD17B13 expression
granted -
US 12410225
Modulation of dendritic cell lineages
granted -
US 12410430
Modulating apolipoprotein (A) expression
granted -
US 12364753
CD8 binding agents
granted -
US 12351633
PD-1 and PD-L1 binding agents
granted -
US 12350285
Compounds and methods for reducing ATXN3 expression
granted -
US 12351614
CLEC9A-based chimeric protein complexes
granted -
US 12343357
Compositions and methods for modulating MECP2 expression
granted
Frequently asked questions
What is US patent 10619157?
US 10619157 (Cancer treatment) is held by Ionis Pharmaceuticals, Inc.. Status: granted. Granted Apr 14, 2020. Expires Apr 9, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10619157?
Ionis Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 222 pharmaceutical patents for this assignee.
When does US 10619157 expire?
Our index shows an expiration date of Apr 9, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.